Search Results - "Petutschnigg, Johannes"

The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial by Kobayashi, Masatake, Girerd, Nicolas, Ferreira, João Pedro, Kevin, Duarte, Huttin, Olivier, González, Arantxa, Bozec, Erwan, Clark, Andrew L., Cosmi, Franco, Cuthbert, Joe, Diez, Javier, Edelmann, Frank, Hazebroek, Mark, Heymans, Stephane, Mariottoni, Beatrice, Pellicori, Pierpaolo, Petutschnigg, Johannes, Pieske, Burkert, Staessen, Jan A., Verdonschot, Job A.J., Rossignol, Patrick, Cleland, John G.F., Zannad, Faiez

“…Aims Procollagen type I C‐terminal propeptide (PICP) and procollagen type III N‐terminal propeptide (PIIINP) are markers reflecting collagen synthesis in…”
Get full text

The diagnostic and prognostic value of galectin‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study by Trippel, Tobias Daniel, Mende, Meinhard, Düngen, Hans‐Dirk, Hashemi, Djawid, Petutschnigg, Johannes, Nolte, Kathleen, Herrmann‐Lingen, Christoph, Binder, Lutz, Hasenfuss, Gerd, Pieske, Burkert, Wachter, Rolf, Edelmann, Frank

“…Aims Galectin‐3 (Gal‐3) predicts long‐term outcome among patients with heart failure (HF) with preserved ejection fraction (HFpEF). The ability of Gal‐3 to…”
Get full text

Evaluation of the HFA‐PEFF Score: results from the prospective DIAST‐CHF cohort by Hashemi, Djawid, Mende, Meinhard, Trippel, Tobias D., Petutschnigg, Johannes, Hasenfuss, Gerd, Nolte, Kathleen, Herrmann‐Lingen, Christoph, Feuerstein, Anna, Langhammer, Romy, Tschöpe, Carsten, Pieske, Burkert, Wachter, Rolf, Edelmann, Frank

“…Aims Although the number of patients suffering from heart failure with preserved ejection fraction (HFpEF) increases, the routine diagnosis remains a…”
Get full text

Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial by Verdonschot, Job A J, Ferreira, João Pedro, Pellicori, Pierpaolo, Brunner-La Rocca, Hans-Peter, Clark, Andrew L, Cosmi, Franco, Cuthbert, Joe, Girerd, Nicolas, Mariottoni, Beatrice, Petutschnigg, Johannes, Rossignol, Patrick, Cleland, John G F, Zannad, Faiez, Heymans, Stephane R B

“…Patients with diabetes mellitus (DM) are at increased risk of developing heart failure (HF). The "Heart OMics in AGEing" (HOMAGE) trial suggested that…”
Get full text

Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial by Santos‐Ferreira, Diogo, Diaz, Sílvia O., Ferreira, João Pedro, Girerd, Nicolas, Pellicori, Pierpaolo, Mariottoni, Beatrice, Cosmi, Franco, Hazebroek, Mark, Verdonschot, Job A.J., Cuthbert, Joe, Petutschnigg, Johannes, Heymans, Stephane, Staessen, Jan A., Pieske, Burkert, Edelmann, Frank, Clark, Andrew L., Rossignol, Patrick, Fontes‐Carvalho, Ricardo, Cleland, John G.F., Zannad, Faiez

“…Aims We aim to characterize the clinical and proteomic profiles of patients at risk of developing heart failure (HF), with and without coronary artery disease…”
Get full text

Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial by Monzo, Luca, Ferreira, João Pedro, Cleland, John G.F., Pellicori, Pierpaolo, Mariottoni, Beatrice, Verdonschot, Job A.J., Hazebroek, Mark R., Collier, Tim J., Cuthbert, Joe J., Pieske, Burkert, Edelmann, Frank, Petutschnigg, Johannes, Khan, Javed, Ahmed, Fozia Z., Girerd, Nicolas, Bozec, Erwan, Díez, Javier, González, Arantxa, Clark, Andrew L., Cosmi, Franco, Staessen, Jan A., Heymans, Stephane, Rossignol, Patrick, Zannad, Faiez

“…Aims In people at risk of heart failure (HF) enrolled in the Heart ‘OMics’ in AGEing (HOMAGE) trial, spironolactone reduced circulating markers of collagen…”
Get full text

Economic impact of heart failure with preserved ejection fraction: insights from the ALDO‐DHF trial by Hashemi, Djawid, Dettmann, Ludwig, Trippel, Tobias D., Holzendorf, Volker, Petutschnigg, Johannes, Wachter, Rolf, Hasenfuß, Gerd, Pieske, Burkert, Zapf, Antonia, Edelmann, Frank

“…Aims Although heart failure (HF) with preserved ejection fraction (HFpEF) is a leading cause for hospitalization, its overall costs remain unclear. Therefore,…”
Get full text

Closing the gap, or the beauty of alleviating our patients' symptoms by Petutschnigg, Johannes, Edelmann, Frank

Get full text

The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial by Cleland, John G F, Ferreira, João Pedro, Mariottoni, Beatrice, Pellicori, Pierpaolo, Cuthbert, Joe, Verdonschot, Job A J, Petutschnigg, Johannes, Ahmed, Fozia Z, Cosmi, Franco, Brunner La Rocca, Hans-Peter, Mamas, Mamas A, Clark, Andrew L, Edelmann, Frank, Pieske, Burkert, Khan, Javed, McDonald, Ken, Rouet, Philippe, Staessen, Jan A, Mujaj, Blerim, González, Arantxa, Diez, Javier, Hazebroek, Mark, Heymans, Stephane, Latini, Roberto, Grojean, Stéphanie, Pizard, Anne, Girerd, Nicolas, Rossignol, Patrick, Collier, Tim J, Zannad, Faiez

“…Abstract Aims  To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure. Methods…”
Get full text

Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials by Ferreira, João Pedro, Cleland, John G., Girerd, Nicolas, Bozec, Erwan, Rossignol, Patrick, Pellicori, Pierpaolo, Cosmi, Franco, Mariottoni, Beatrice, Solomon, Scott D., Pitt, Bertram, Pfeffer, Marc A., Shah, Amil M., Petutschnigg, Johannes, Pieske, Burkert, Edelmann, Frank, Zannad, Faiez

“…Aims Spironolactone is currently used in a large proportion of patients with heart failure and preserved ejection fraction (HFpEF), yet its effect on cardiac…”
Get full text

Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial by Pellicori, Pierpaolo, Ferreira, João Pedro, Mariottoni, Beatrice, Brunner‐La Rocca, Hans‐Peter, Ahmed, Fozia Z., Verdonschot, Job, Collier, Tim, Cuthbert, Joe J., Petutschnigg, Johannes, Mujaj, Blerim, Girerd, Nicolas, González, Arantxa, Clark, Andrew L., Cosmi, Franco, Staessen, Jan A., Heymans, Stephane, Latini, Roberto, Rossignol, Patrick, Zannad, Faiez, Cleland, John G.F.

“…Aims Asymptomatic patients with coronary artery disease (CAD), hypertension and/or type 2 diabetes mellitus (T2DM) are at greater risk of developing heart…”
Get full text

Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial) by Ferreira, João Pedro, Cleland, John G.F., Girerd, Nicolas, Pellicori, Pierpaolo, Hazebroek, Mark R., Verdonschot, Job, Collier, Timothy J., Petutschnigg, Johannes, Clark, Andrew L., Staessen, Jan A., Heymans, Stephane, Rossignol, Patrick, Zannad, Faiez

“…The QRS duration can be easily obtained from a 12-lead electrocardiogram. Increased QRS duration reflects greater ventricular activation times and often…”
Get full text

Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials by Ferreira, João Pedro, Cleland, John G., Girerd, Nicolas, Rossignol, Patrick, Pellicori, Pierpaolo, Cosmi, Franco, Mariottoni, Beatrice, González, Arantxa, Diez, Javier, Solomon, Scott D., Claggett, Brian, Pfeffer, Marc A., Pitt, Bertram, Petutschnigg, Johannes, Pieske, Burkert, Edelmann, Frank, Zannad, Faiez

“…Spironolactone might improve the prognosis of patients with heart failure with preserved left ventricular ejection fraction (HFpEF), but the mechanisms by…”
Get full text

Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF by Ferreira, João Pedro, Verdonschot, Job, Wang, Ping, Pizard, Anne, Collier, Timothy, Ahmed, Fozia Z., Brunner-La-Rocca, Hans-Peter, Clark, Andrew L., Cosmi, Franco, Cuthbert, Joe, Díez, Javier, Edelmann, Frank, Girerd, Nicolas, González, Arantxa, Grojean, Stéphanie, Hazebroek, Mark, Khan, Javed, Latini, Roberto, Mamas, Mamas A., Mariottoni, Beatrice, Mujaj, Blerim, Pellicori, Pierpaolo, Petutschnigg, Johannes, Pieske, Burkert, Rossignol, Patrick, Rouet, Philippe, Staessen, Jan A., Cleland, John G.F., Heymans, Stephane, Zannad, Faiez

“…This study sought to further understand the mechanisms underlying effect of spironolactone and assessed its impact on multiple plasma protein biomarkers and…”
Get full text

Biomarker‐based assessment of collagen cross‐linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial by Ravassa, Susana, López, Begoña, Ferreira, João Pedro, Girerd, Nicolas, Bozec, Erwan, Pellicori, Pierpaolo, Mariottoni, Beatrice, Cosmi, Franco, Hazebroek, Mark, Verdonschot, Job A.J., Cuthbert, Joe, Petutschnigg, Johannes, Moreno, María U., Heymans, Stephane, Staessen, Jan A., Pieske, Burkert, Edelmann, Frank, Clark, Andrew L., Cleland, John G.F., Zannad, Faiez, Díez, Javier, González, Arantxa

“…Aims The HOMAGE randomized trial found that spironolactone reduced left atrial volume index (LAVI), E:A ratio, and a marker of collagen type I synthesis…”
Get full text

Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort by Kobayashi, Masatake, Ferreira, João Pedro, Duarte, Kevin, Bresso, Emmanuel, Huttin, Olivier, Bozec, Erwan, Brunner La Rocca, Hans‐Peter, Delles, Christian, Clark, Andrew L., Edelmann, Frank, González, Arantxa, Heymans, Stephane, Pellicori, Pierpaolo, Petutschnigg, Johannes, Verdonschot, Job A.J., Rossignol, Patrick, Cleland, John G.F., Zannad, Faiez, Girerd, Nicolas

“…Aims High left ventricular filling pressure increases left atrial volume and causes myocardial fibrosis, which may decrease with spironolactone. We studied…”
Get full text

Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial by Ferreira, João Pedro, Verdonschot, Job A.J., Girerd, Nicolas, Bozec, Erwan, Pellicori, Pierpaolo, Collier, Timothy, Mariottoni, Beatrice, Cosmi, Franco, Hazebroek, Mark, Cuthbert, Joe, Petutschnigg, Johannes, Heymans, Stephane, Staessen, Jan A., Pieske, Burkert, Edelman, Frank, Clark, Andrew L., Díez, Javier, González, Arantxa, Rossignol, Patrick, Cleland, John G., Zannad, Faiez

“…Aims Left ventricular ejection fraction (LVEF) can provide haemodynamic information and may influence the response to spironolactone and other heart failure…”
Get full text

A machine learning‐derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial by Kobayashi, Masatake, Huttin, Olivier, Ferreira, João Pedro, Duarte, Kevin, González, Arantxa, Heymans, Stephane, Verdonschot, Job A.J., Brunner‐La Rocca, Hans‐Peter, Pellicori, Pierpaolo, Clark, Andrew L., Petutschnigg, Johannes, Edelmann, Frank, Cleland, John G., Rossignol, Patrick, Zannad, Faiez, Girerd, Nicolas

“…Aim An echocardiographic algorithm derived by machine learning (e′VM) characterizes pre‐clinical individuals with different cardiac structure and function,…”
Get full text

Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial by Yu, Yu-Ling, Siwy, Justyna, An, De-Wei, González, Arantxa, Hansen, Tine, Latosinska, Agnieszka, Pellicori, Pierpaolo, Ravassa, Susana, Mariottoni, Beatrice, Verdonschot, Job Aj, Ahmed, Fozia, Petutschnigg, Johannes, Rossignol, Patrick, Heymans, Stephane, Cuthbert, Joe J, Girerd, Nicolas, Clark, Andrew L, Verhamme, Peter, Nawrot, Tim S, Janssens, Stefan, Cleland, John G, Zannad, Faiez, Diez, Javier, Mischak, Harald, Ferreira, João Pedro, Staessen, Jan A

“…Heart failure (HF) is characterised by collagen deposition. Urinary proteomic profiling (UPP) followed by peptide sequencing identifies parental proteins, for…”
Get more information

Non-eligibility for pivotal HFpEF/HFmrEF outcome trials and mortality in a contemporary heart failure cohort by Santner, Viktoria, Riepl, Hermann S, Posch, Florian, Wallner, Markus, Rainer, Peter P, Ablasser, Klemens, Kolesnik, Ewald, Hoeller, Viktoria, Zach, David, Schwegel, Nora, Kreuzer, Philipp, Lueger, Andreas, Petutschnigg, Johannes, Pieske, Burkert, Zirlik, Andreas, Edelmann, Frank, Verheyen, Nicolas

“…Pivotal outcome trials targeting heart failure with preserved (HFpEF) and mildly-reduced ejection fraction (HFmrEF) may have excluded patients at highest risk…”
Get full text